Erschienen in:
29.04.2020 | Letter to the Editor
Anti-HER2 therapy for metastatic breast cancer in low- and middle-income countries: bridging the gap between clinical trials and real life
verfasst von:
Leonardo Ribeiro Soares, Victor Domingos Lisita Rosa, Ruffo Freitas-Junior
Erschienen in:
Breast Cancer Research and Treatment
|
Ausgabe 3/2020
Einloggen, um Zugang zu erhalten
Excerpt
We read with great interest the work of Gong et al. [
1], which addressed the differences in clinical outcomes in women with HER2-positive metastatic breast cancer (MBC) conducted in clinical trials and in real life. In the population-based cohort, the overall survival observed in populations treated with trastuzumab/pertuzumab (39.2 months) and T-DM1 (15.4 months) was lower than that observed in the respective pivotal clinical trials (56.4 and 30.9 months, respectively). …